CAPTRUST Financial Advisors
DNLI icon

CAPTRUST Financial Advisors’s Denali Therapeutics DNLI Stock Holding History

CAPTRUST Financial Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-146
Closed -$4K – 2569
2022
Q2 		$4K Sell
146
-25
-15% -$655 ﹤0.01% 4175
2022
Q1 		$6K Buy
171
+52
+44% +$1.79K ﹤0.01% 4055
2021
Q4 		$5K Buy
+119
New +$5.64K ﹤0.01% 4056

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CAPTRUST Financial Advisors's DNLI Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 146 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in DNLI in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q1 2022. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 146 Denali Therapeutics shares in Q3 2022, an estimated $4K.
  • CAPTRUST Financial Advisors first reported a position in Denali Therapeutics in Q4 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Denali Therapeutics position peaked at $6K in Q1 2022.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.